Latest news with #ChronicKidneyDisease
The Hindu
15 hours ago
- Health
- The Hindu
Karnataka's Health Department extends Gruha Arogya scheme across State
For early detection and management of non-communicable diseases (NCD) among people in rural areas, Karnataka's Health Department has now extended the Gruha Arogya (doorstep healthcare) scheme across the State. The scheme that was formally launched by Chief Minister Siddaramaiah on October 24 last year was initially piloted in Kolar district, where dedicated health teams conducted door-to-door screening for major NCDs. Following its success, the initiative is now being scaled up to all districts, announced Health Minister Dinesh Gundu Rao on Monday. Major NCDs During the pilot project, screening was conducted for major NCDs, including Diabetes, Hypertension, three common cancers - Oral, Breast and Cervical cancer (the latter two for females) in individuals aged 30 years and above. Now, ASHA workers will conduct door-to-door visits to raise awareness about NCDs and facilitate health check-ups for individuals above 30 at Ayushman Health and Wellness Centres. Community Health Officers (CHOs) will conduct screenings for 14 NCDs, including hypertension, diabetes, and cancer, and record the data on the NCD portal. Free medication and regular follow-up care will be provided at the nearest Ayushman Health and Wellness centres to those diagnosed, the Minister said. Apart from Diabetes, Hypertension, Oral Cancer, Breast Cancer, Cervical Cancer, the other NCDs to be covered under the scheme include Diabetic Foot, Mental Health Disorders, Neurological Disorders, Obstructive Sleep Apnea, Diabetic Retinopathy, Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD), Non-Alcoholic Fatty Liver Disease (NAFLD) and Anemia (19-29 yrs). Five houses a day Srinivas G., State Deputy Director (Non-Communicable Diseases) said ASHA workers will visit the households under their jurisdiction on all working days of the week (excluding State-declared holidays), covering approximately four to five houses per day. During these visits, they will register all members of the household in the ASHA application on the NCD portal. The CHOs, who will provide screening, diagnosis, management, and treatment of all NCDs for individuals aged 30 years and above, will refer the suspected cases and patients with diabetes for confirmation through tele-consultation. 'CHOs will conduct screening, management and treatment services for walk-in patients at Ayushman Health Centres every Monday, Tuesday, Thursday and Saturday. On Wednesdays and Fridays, CHOs will conduct outreach activities and organise NCD screening camps in coordination with ASHA workers,' he said. 'Patients under treatment will receive regular follow-up, including re-examinations and necessary support for a period of up to two months,' he added.
Globe and Mail
16-05-2025
- Health
- Globe and Mail
Anemia in Chronic Kidney Disease Market Set for Significant Growth and Innovation by 2034
Anemia in Chronic Kidney Disease (CKD), a common and debilitating complication resulting from reduced erythropoietin production and iron deficiency, continues to pose serious clinical challenges and an economic burden. DelveInsight's comprehensive report on the Anemia in CKD market sheds light on the evolving understanding and management of this condition, which affects a substantial proportion of patients with moderate to advanced CKD. With improved awareness and screening, earlier diagnosis and intervention are becoming more achievable, especially with the support of emerging biomarkers and treatment guidelines. Innovative therapies such as HIF-PH inhibitors and long-acting erythropoiesis-stimulating agents (ESAs) are shaping a dynamic treatment landscape aimed at improving hemoglobin levels with fewer side effects. DelveInsight's ' Anemia in Chronic Kidney Disease Market Report ' offers an in-depth analysis of the epidemiology, disease burden, and market outlook across key geographies, including the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report highlights current unmet needs, late-stage pipeline therapies, market drivers and barriers, and the key players transforming patient care, making it a vital resource for healthcare stakeholders and innovators in nephrology. Some of the Key Facts of the Anemia in Chronic Kidney Disease Market Report: • The anemia in chronic kidney disease is expected to grow at a significant CAGR by 2034. • In 2023, the United States recorded the highest number of prevalent Anemia in Chronic Kidney Disease (CKD) cases among the 7MM. • The U.S. also accounted for the highest number of treated cases of Anemia in CKD during the same year. • A higher prevalence was noted among individuals aged 60 and above compared to those under 60 in the U.S. • Males with CKD had a 30% higher risk of developing anemia compared to females. • Among the EU4 and the UK, Spain reported the lowest number of anemia in CKD cases in 2023. • In Japan, anemia was one of the most frequently documented outcomes, with prevalence rates ranging from 0% to 95%, depending on CKD severity and dialysis status. • In March 2025, the FDA expanded the approval of Furoscix to include the treatment of edema in patients with chronic kidney disease, including nephrotic syndrome. • In March 2025, scPharmaceuticals received FDA approval for a supplemental new drug application (sNDA) for Furoscix (furosemide injection). This approval expands the drug's use to treat edema in patients with chronic kidney disease (CKD), marking a significant advancement in scPharmaceuticals' portfolio for cardiorenal conditions. • In March 2025, the FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to treat edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is expected to be available by April 2025. This approval follows the FDA's acceptance of the supplemental new drug application in July 2024. • In January 2025, the FDA approved a new indication for semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to Novo Nordisk. • In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a PDUFA target action date set for June 28, 2025. If approved, OLC has the potential to significantly enhance the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis. • Leading companies in the anemia in chronic kidney disease market include Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and others. • Emerging therapies in the anemia in chronic kidney disease market include DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others. • The rising prevalence of anemia in chronic kidney disease, along with continuous advancements in therapeutic options, is fueling the demand for more effective treatment approaches. To know in detail about the anemia in chronic kidney disease market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Anemia In Chronic Kidney Disease Market Forecast Anemia in Chronic Kidney Disease Overview Anemia is a frequent and serious complication of Chronic Kidney Disease (CKD), arising as kidney function declines and the body's ability to produce adequate erythropoietin—a hormone essential for red blood cell production, diminishes. CKD impairs the kidneys' filtering ability, leading to the accumulation of waste and fluids, which further contributes to the onset of anemia. The condition becomes increasingly prevalent in advanced stages of CKD. In the United States, over 37 million adults are estimated to have CKD, and more than one in seven individuals with CKD also suffer from anemia. The risk intensifies as kidney function deteriorates, with nearly all individuals at end-stage kidney failure (when kidney function drops below 15%) experiencing anemia. Certain populations are more susceptible: individuals with CKD and diabetes are at higher risk of developing anemia earlier and in more severe forms. Additionally, people over the age of 60 are more likely to be affected. The progression of CKD-related anemia is typically gradual and may remain asymptomatic in its early stages, making early detection and management crucial for improving patient outcomes. Get a free sample of the anemia in chronic kidney disease market report with key insights and emerging therapies here: Anemia in Chronic Kidney Disease Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Anemia in Chronic Kidney Disease Epidemiology Segmentation: The anemia in chronic kidney disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Total Prevalent Cases of Chronic Kidney Disease • Diagnosed Cases of Anemia in Chronic Kidney Disease • Age-Specific Prevalent Cases of Anemia in Chronic Kidney Disease • Total Prevalent Cases of Anemia in Chronic Kidney Disease • Total Prevalent Cases of Anemia in Different Stages of Chronic Kidney Disease • Treatable Cases of Anemia in Chronic Kidney Disease Download the report to understand which factors are driving anemia in chronic kidney disease epidemiology trends @ Anemia In Chronic Kidney Disease Epidemiology Forecast The anemia in chronic kidney disease drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the anemia in chronic kidney disease market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the anemia in chronic kidney disease pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. Anemia in Chronic Kidney Disease Market Strengths • The availability of novel oral treatment options, such as daprodustat, offers more convenient and effective routes of administration for patients. • Active research and ongoing clinical trials are enhancing the understanding of the disease and driving innovation in therapeutic strategies. Anemia in Chronic Kidney Disease Market Weaknesses • Patients often struggle to recognize or differentiate the symptoms of anemia from CKD or other related conditions, leading to underreporting. • Healthcare providers, particularly in non-dialysis settings, frequently under-monitor hemoglobin levels and iron stores, resulting in delayed or suboptimal treatment initiation. Scope of the Anemia in Chronic Kidney Disease Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Anemia In Chronic Kidney Disease Companies: GlaxoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others. • Key Anemia In Chronic Kidney Disease Therapies: DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others. • Anemia In Chronic Kidney Disease Therapeutic Assessment: Anemia in chronic kidney disease, currently marketed, and anemia in chronic kidney disease emerging therapies • Anemia In Chronic Kidney Disease Market Dynamics: Anemia in chronic kidney disease market drivers and anemia in chronic kidney disease market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Anemia In Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Anemia In Chronic Kidney Disease Market Access and Reimbursement To learn more about the key players and advancements in the anemia in chronic kidney disease treatment landscape, visit the Table of Contents 1. Anemia In Chronic Kidney Disease Market Report Introduction 2. Executive Summary for Anemia In Chronic Kidney Disease 3. SWOT analysis of Anemia In Chronic Kidney Disease 4. Anemia In Chronic Kidney Disease Patient Share (%) Overview at a Glance 5. Anemia In Chronic Kidney Disease Market Overview at a Glance 6. Anemia In Chronic Kidney Disease Disease Background and Overview 7. Anemia In Chronic Kidney Disease Epidemiology and Patient Population 8. Country-Specific Patient Population of Anemia In Chronic Kidney Disease 9. Anemia In Chronic Kidney Disease Current Treatment and Medical Practices 10. Anemia In Chronic Kidney Disease Unmet Needs 11. Anemia In Chronic Kidney Disease Emerging Therapies 12. Anemia In Chronic Kidney Disease Market Outlook 13. Country-Wise Anemia In Chronic Kidney Disease Market Analysis (2020–2034) 14. Anemia In Chronic Kidney Disease Market Access and Reimbursement of Therapies 15. Anemia In Chronic Kidney Disease Market Drivers 16. Anemia In Chronic Kidney Disease Market Barriers 17. Anemia In Chronic Kidney Disease Appendix 18. Anemia In Chronic Kidney Disease Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Borneo Post
11-05-2025
- Health
- Borneo Post
Less than a third of Malaysians with chronic kidney disease know they have it, says nephrologist
Dr Tan delivers her talk at the launch of the World Kidney Day 2025 held at The Hills here today. – Photo by Jude Toyat KUCHING (May 11): Chronic kidney disease (CKD) is a silent but escalating health crisis in Malaysia, with over 15.5 per cent of the population estimated to be affected — yet less than one third of these patients are aware they have the disease. Sarawak General Hospital (SGH) consultant nephrologist Dr Clare Tan disclosed this during her health talk titled 'Chronic Kidney Disease (CKD): The Silent Threat' in conjunction with the World Kidney Day 2025 held at a shopping mall here today. 'Only about five per cent of people with chronic kidney disease are actually aware of their condition. That means the vast majority are completely unaware that their kidneys are slowly failing,' she said. Dr Tan warned that CKD often presents no symptoms in its early stages, with many individuals only discovering they have the disease when it has reached an advanced stage or progressed to kidney failure, requiring dialysis. She disclosed that more than 50,000 Malaysians are currently undergoing dialysis therapy due to end-stage kidney failure, and that number continues to rise annually. In 2022 alone, over 10,000 new patients began dialysis. In Sarawak, 4,800 individuals are currently on dialysis, with numbers steadily climbing. However, she stressed that these figures only represent the 'tip of the iceberg.' 'There are many more Malaysians living with earlier stages of chronic kidney disease. If not properly managed, these patients will eventually progress to kidney failure and require dialysis. Early detection is the key to preventing that,' she said. According to national surveys conducted in 2011 and 2018, the prevalence of CKD in Malaysia rose sharply from nine per cent to 15.5 per cent — a staggering increase in just seven years. This means that about one in six to seven Malaysians may have CKD. Dr Tan attributed the rise to lifestyle-related risk factors, particularly diabetes and high blood pressure. 'In Malaysia, 53 per cent of patients on dialysis developed kidney failure due to diabetes, while another 30 per cent was due to hypertension. Combined, these two causes account for more than 80 per cent of all dialysis cases,' she explained. The rising incidence of obesity is another emerging risk factor. In 2023, over 54 per cent of Malaysians had a body mass index (BMI) above 25, indicating overweight or obesity. This is significant, as studies show that obesity increases the risk of CKD, especially when combined with diabetes or hypertension. Dr Tan also highlighted a worrying trend — CKD and diabetes are affecting increasingly younger Malaysians. 'Young people often don't realise they can have diabetes or high blood pressure. Without regular check-ups, many go undiagnosed until complications like kidney failure arise,' she said. The financial burden of CKD is also substantial. Patients on dialysis often suffer from multiple health complications, including heart problems and infections, which increase hospitalisation and healthcare costs. The government spends substantial resources to provide dialysis treatment and manage associated health issues. Because early CKD is often symptomless, Dr Tan urged Malaysians — especially those with risk factors such as diabetes, hypertension, obesity, family history of kidney disease, or a history of taking chronic painkillers — to undergo regular screenings. 'Screening is simple. It just involves a blood test to check kidney function and a urine test for protein leakage,' she said. 'For high-risk individuals, especially those with diabetes or high blood pressure, annual screening is strongly recommended.' Early detection enables timely intervention that can slow disease progression. 'If we can detect kidney disease early, control the underlying conditions like diabetes and hypertension, and use medications that reduce protein loss in the urine, we can delay or even prevent the need for dialysis,' Dr Tan said. She concluded with a powerful reminder: 'Chronic kidney disease is common, dangerous, and often silent. But it is not hopeless. With awareness, screening, and early intervention, we can save kidneys — and lives.' World Kidney Day 2025 is celebrated annually to raise awareness of kidney health and promote preventive health measures. chronic kidney disease diabetes Dr Clare Tan hypertension lead
Time of India
02-05-2025
- Health
- Time of India
Why do some patients need a transplant after kidney dialysis ?
Kidney disease is a common health condition, affecting thousands of individuals every year. The severity of kidney disease is variable, while those with mild to moderate renal dysfunction can be managed with medications , patients with severe renal dysfunction may need renal replacement therapy like dialysis . Kidney damage can be temporary like in Acute Kidney Injury (AKI) where the kidney damage is due to a reversible cause like dehydration or toxins – In such patients with severe renal damage dialysis is a temporary measure till the renal function recovers. Such patients do not need a renal transplant. However patients with Chronic Kidney Disease (CKD) who have had a progressive worsening of their renal functions may progress to End Stage Kidney Disease (ESKD) – Such patients will need regular dialysis as their renal functions are unlikely to recover. In patients with ESKD, Renal transplant is the best available treatment modality as the new kidney replaces the renal function of the non functioning kidneys and the patient does not need dialysis after renal transplant. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Your Finger Shape Says a Lot About Your Personality, Read Now Tips and Tricks Undo In other words patients with ESKD need to be on dialysis until they can undergo a renal transplant. Some patients who are very ill may not be fit for a renal transplant and hence may be managed with dialysis only. However the Achilles heel of renal transplant is the availability of suitable renal donor. A living donor must ideally be related to the patient and have same blood group as the patient or have O group blood. Moreover the donor must have no chronic illness like diabetes and be fit enough to lead a normal life with single kidney after donating one kidney – hence a living renal donor undergoes a battery of tests to evaluate fitness for renal donation. Patients who do not have a suitable living renal donor may be considered for a cadaveric donor. However the number of patients on waitlist for transplant far outnumbers the number of available cadaveric donors. Though the awareness about cadaveric organ donation is improving among the general public due multiple government and media interventions – still more activity is needed in this area. Dialysis or Kidney Transplant? Choosing whether you should go for dialysis or kidney transplant in ESKD is based on several factors . For instance, dialysis is more suitable as an immediate treatment for failed kidneys. It is a non-surgical procedure and does not depend on donor availability. Moreover, it is the best treatment modality for ESKD individuals who do not fall in the safe category for getting a transplant. Alternatively, kidney transplant is ideal for people suffering from ESKD who are looking for more effective and long-term solution and have a suitable renal donor. Bottomline: A patient with temporary kidney damage (AKI) needs dialysis till the time the kidney recovers on treatment of the underlying cause of AKI. However a patient with ESKD will need dialysis until they undergo renal transplant – provided they get a suitable renal donor (live or cadaveric) and is fit for the surgical procedure. (Article courtesy: Dr. Navinath M MD(Med), DM(Nephro), DNB(Nephro), MNAMS, Consultant Nephrologist and Renal Transplant Physician, Asian Institute of Nephrology and Urology, Nungambakkam, Chennai.) Infected kidneys hold promise for transplants
Indian Express
25-04-2025
- Health
- Indian Express
Protein deficiency? How to get 60 gm daily from natural food and not depend on supplements
When a 32-year-old patient with protein deficiency came to meet Bhakti Samant, chief dietician at Kokilaben Dhirubhai Ambani Hospital, Mumbai, he had thought she would prescribe a protein supplement. But he was surprised when she told him he did not need any supplement at all and gave him a diet chart that had whole food sources of protein spread across meals and snacks. He is now fit and energetic. 'All he needed was to balance his diet with protein in every meal to meet his daily requirement. This is the myth that everybody falls for, that protein from natural foods is not enough to meet your nutritional requirement. The body needs 0.8 gm-1gm of protein per kg of body weight to avoid deficiencies. Unless one is an athlete or recovering from illness, any normal, healthy person can easily get between 60 gm to 65 gm of protein from natural food sources. Regular people do not need supplements, just practical meal plans,' says Samant. WHY INDIA LAGS BEHIND PROTEIN TARGETS? All nutritional guidelines suggest that 10-35% of our daily calories should come from protein-rich foods. 'Estimates show that only 10 to 11 per cent of the Indian diet is protein, compared to 12 to 15 per cent in the US. We are stuck at a consumption level of 0.5 gm per kg of body weight. That's because we are largely vegetarians, with plant proteins not quite matching up to animal ones. But the bigger problem is behavioural. Our diets are carbohydrate-heavy. By not having enough protein (a quarter of your plate in every meal), you are creating a protein vacuum which you fill up with more carbohydrates, the root cause of blood sugar, inflammation and other problems,' says Dr Seema Gulati of the National Diabetes, Obesity and Cholesterol Foundation (NDOC) Centre for Nutrition Research, Delhi. Myths around having protein-rich diets pose another challenge, according to Ritika Samaddar, regional head, Clinical Nutrition and Dietetics, Max Healthcare. 'While animal protein is easier to incorporate, even plant proteins, in the right variety and combinations, can easily meet your daily protein requirement. Some plant-based sources like soy (tofu, soy milk), quinoa and chia seeds offer all nine essential amino acids. Plus they don't have saturated fat,' she says. WHAT ARE THE MYTHS AROUND DIETARY PROTEIN? Most of Samaddar's patients feel that a protein-rich diet is only for athletes and bodybuilders. 'Apart from building muscle, repairing tissues and producing hormones, proteins lend satiety, prevent quick breakdown of sugar and keep hunger pangs at bay, managing both weight and calories,' she says. Many believe high protein diets harm the kidneys. Yet a moderate protein intake with hydration is safe for most people. 'What many don't know is that even patients of Chronic Kidney Disease (CKD), not on dialysis, need 0.6 gm of protein per kg of body weight per day. Those on dialysis need 1.0-1.2 gm per kg of body weight per day, and that too from whole food sources. Yet such patients don't have more than 0.2 per gm per kg of body weight,' says Samant. The elderly, too, require 1 to 1.2 gm per kg body weight to avoid sarcopenia, a progressive wasting of muscle and skeletal mass. HOW EASY IS IT TO GET DAILY PROTEIN QUOTA FROM DIETARY SOURCES Dr Gulati has a chart ready. 'Let's assume you need between 60 to 65 gm of protein per day. Let's begin with pre-breakfast, where you can have 10 nuts, soaked or raw, all yielding between 3 gm to 26 gm, depending on the portion. You can even split them into two parts. For breakfast you can have moong dal chila, which yields 9 gm of protein per serving, so two would be 18 gm with chutney. Have a tofu salad which can give you 20 gm straight per 100 gram or a cup. Have a glass (200 ml) of buttermilk which amounts to 15 gm of protein,' she says. For lunch, she recommends multigrain millet rotis (4 to 7 gm from two diskettes) a cup of dal (12 to 20 gm), sauteed vegetables (between 2 to 4 gm per 100 g), which should be half your plate, and a bowl of curd (15 gm). Round it off with a cup of warm milk (3 to 4 gm). Snacks can be about roasted chickpeas (15 gm), a cup of grilled paneer (46 gm) cubes or sprouts (3 to 6 gm per 100 gm). For dinner, Dr Gulati recommends besan roti (a 30 gm roti contains around 6.6 gm of protein) or soybean flour roti (4.6 gm per roti), paneer, vegetables and curd (as listed above). For beverages, one can have a sattu drink (7 to 8 gm). 'There are enough high value plant proteins that can more than make up for your quota,' she says. For those used to animal protein, eggs (6 gm per egg), fish (a large piece or two small pieces contain 20 g protein) and chicken (24 to 32 gm per 100 gm, which is a biggish piece) are good sources. 'These in combination with plant proteins provide a rich bioavailable source. Who needs supplements then?' asks Dr Gulati. WHAT IS THE BIG MISTAKE THAT WE MAKE? Samant says most of us load up on protein in one or two meals and think we are done for the day. 'Remember the body can absorb only 20 to 25 gm of protein at a time. So if you have extra protein in a single meal, the surplus will go into storage as fat. That's why you need to evenly distribute protein intake through the day for the best results,' she adds. That way you can keep your normal protein range between 6.0 and 8.3 g/dL.
